XPHvsSBIOETF Comparison
VS
State Street SPDR S&P Pharmaceuticals ETF (XPH) belongs to the US Health Care segment. ALPS Medical Breakthroughs ETF (SBIO) is part of the Tomorrow's Treatments segment. XPH's top 1 sector exposures are Healthcare. In contrast, SBIO's top sector exposures are Healthcare and Non-Corporate. XPH is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.5% for SBIO. XPH is up 14.29% year-to-date (YTD) with +$186M in YTD flows. SBIO performs worse with 8.39% YTD performance, and +$58M in YTD flows. Run a side-by-side ETF comparison of XPH and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XPH vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XPH SBIO | -4.31%-5.02% | -6.56%-13.92% | +14.29%+8.39% | +30.94%+24.99% | +86.70%+144.50% | +44.35%+27.09% |
| Flows | XPH SBIO | -$80M-$14M | +$11M+$17M | +$186M+$58M | +$206M+$90M | +$160M+$42M | +$157M+$2M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XPH SBIO | +22.82%+32.48% | +23.36%+32.19% | +20.82%+31.51% | +21.10%+34.24% |
| Max drawdown | XPH SBIO | -16.58%-29.19% | -16.58%-29.19% | -23.45%-42.12% | -30.87%-52.50% |
| Max drawdown duration | XPH SBIO | 69d69d | 69d69d | 322d331d | 1452d1479d |
Trading data
XPH | SBIO | |
Last sale 10/28/2026 at 1:30 PM | $64.55 | $56.09 |
| Previous close 10/27/2026 | $63.96 | $55.48 |
| Consolidated volume 10/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XPH | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/28/2026 at 1:30 PM
Live
Closed
XPH | SBIO | |
|---|---|---|
| Last price | $64.55 | $56.09 |
| 1D performance | +0.92% | +1.10% |
| AuM | $447.54 M | $187.04 M |
| E/R | 0.35% | 0.5% |
Characteristics
XPH | SBIO | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | ALPS |
| Benchmark | S&P Pharmaceuticals Select Industry Index | S-Network Medical Breakthroughs Index |
| N° of holdings | 62 | 104 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 19, 2006 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
XPH
USA
89.77%
Other
10.23%
SBIO
USA
89.31%
Other
10.69%
Sectors
XPH
Healthcare
93.27%
Other
6.73%
SBIO
Healthcare
100.01%
Other
-0.01%
Diversification
XPH
Total weight of top 15 holdings out of 15
34.13%
SBIO
Total weight of top 15 holdings out of 15
41.55%
Top 15 holdings
Data as of August 31, 2026
XPH
Amylyx Pharmaceuticals, Inc.
3.65%
Crinetics Pharmaceuticals, Inc.
3.60%
MBX Biosciences, Inc.
2.89%
Omeros Corp.
2.68%
Enliven Therapeutics, Inc.
2.28%
Nuvation Bio, Inc.
2.12%
Corcept Therapeutics, Inc.
2.11%
Eton Pharmaceuticals, Inc.
2.08%
Perrigo Co. Plc
1.91%
Edgewise Therapeutics, Inc.
1.85%
Nektar Therapeutics
1.83%
Merck & Co., Inc.
1.81%
Trevi Therapeutics, Inc.
1.80%
Tarsus Pharmaceuticals, Inc.
1.76%
Bristol Myers Squibb Co.
1.75%
SBIO
Crinetics Pharmaceuticals, Inc.
4.60%
Apogee Therapeutics, Inc.
4.29%
CG Oncology, Inc.
3.41%
Travere Therapeutics, Inc.
3.16%
Xenon Pharmaceuticals, Inc.
2.99%
Dianthus Therapeutics, Inc.
2.96%
Oruka Therapeutics, Inc.
2.87%
ACADIA Pharmaceuticals, Inc.
2.54%
Edgewise Therapeutics, Inc.
2.31%
Definium Therapeutics, Inc.
2.23%
Dyne Therapeutics, Inc.
2.16%
Veradermics, Inc.
2.11%
Relay Therapeutics, Inc.
2.05%
Denali Therapeutics, Inc.
1.94%
Amylyx Pharmaceuticals, Inc.
1.93%
Frequently asked questions about XPH and SBIO
How have the XPH and SBIO ETFs performed in 2026?
As of October 27, 2026, XPH is up 14.29% year-to-date (YTD), while SBIO has returned 8.39%. That puts XPH better performer ahead so far this year.
Which ETF is attracting more investor money: XPH or SBIO?
Year-to-date, the XPH ETF saw +$186M in flows, compared to +$58M for SBIO.
Which ETF is more volatile: XPH or SBIO?
Over the past year, XPH had a volatility of 23.36%, while SBIO experienced 32.19%.
Which ETF is bigger: XPH or SBIO?
As of October 27, 2026, XPH holds $447.54 M in assets under management (AUM), while SBIO manages $187.04 M.
What sectors do the XPH and SBIO ETFs invest in?
XPH leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the XPH ETF and SBIO ETF?
XPH top holdings include Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and MBX Biosciences, Inc.. SBIO holds in its top three: Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc..
Which ETF is more diversified: XPH or SBIO?
XPH holds 62 securities with 34.13% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 41.55%.
Advertisement
Latest news about XPH & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
